By Monica Heger
Illumina has created a new business segment that will focus on the clinical market, CEO Jay Flatley said during a presentation at the JP Morgan Healthcare conference in San Francisco this week.
The Translational and Consumer Genomics segment will be headed up by Matt Posard and will focus on services, the consumer market, CLIA certification and regulations, and business-to-business.
Illumina previously said during its 2011 third-quarter earnings call that it planned to establish a clinically focused business unit as part of a restructuring plan that included the layoff of 200 employees (IS 10/25/2011 and 11/1/2011).
Flatley noted in his presentation this week that clinical sequencing is a particularly rapid growing market, and predicted that the new business unit could see as much as 75 percent growth over the next few years.
Additionally, he provided some estimates for market potential of different areas of the clinical sequencing market. At a $1,000-per-genome price point, sequencing in clinical trials will be a $24 million market in the next few years, while cancer sequencing will be a $250 million market and newborn sequencing around a $350 million market.
Ultimately, though, "the biggest market will be the consumer market," he said.
Have topics you'd like to see covered by Clinical Sequencing News? Contact the editor at mheger [at] genomeweb [.] com.